Abstract
Pediatric DermatologyVolume 37, Issue 5 p. 1002-1002 CORRIGENDUMFree Access Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis This article corrects the following: Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis Elaine C. Siegfried MD, Sean Igelman MD, Jennifer C. Jaworsk MS, Richard J. Antaya MD, Kelly M. Cordoro MD, Lawrence F. Eichenfield MD, Moise L. Levy MD, Amy S. Paller MD, Volume 36Issue 1Pediatric Dermatology pages: 172-176 First Published online: January 24, 2019 First published: 04 August 2020 https://doi.org/10.1111/pde.14288AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In Siegfried et al.,1 Ms. Jaworski's name was originally misspelled in the author list and “dupilumab” was misspelled in the article title. They are correctly listed below. Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis Elaine C. Siegfried MD1,2 | Sean Igelman MD1 | Jennifer C. Jaworski MS3 | Richard J. Antaya MD4 | Kelly M. Cordoro MD5 | Lawrence F. Eichenfield MD6 | Moise L. Levy MD7 | Amy S. Paller MD8 We apologize for this error. REFERENCE 1Siegfried EC, Igelman S, Jaworski JC, et al. Use of dupilumab in pediatric atopic dermatitis: access, dosing, and implications for managing severe atopic dermatitis. Pediatr Dermatol. 2019; 36: 172- 176. https://doi.org/10.1111/pde.13707 Volume37, Issue5September/October 2020Pages 1002-1002 ReferencesRelatedInformation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
